Compound News and Research

RSS

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.

27 Mar 2014

State highlights: Fla. employees' unequal premiums; abuse by Calif. doctor alleged

The Florida Cabinet, state agency managers and legislative staff are among 30,000 top-ranked state workers who will continue to pay ultra-low health insurance premiums in the coming year. In a reverse of the Robin Hood principle, the state charges lower-paid workers six times more than those who have the highest earnings pay. ... [B]oth the House and Senate this week released initial budgets that would keep premiums at the same rate (3/22).

25 Mar 2014

Scientists develop new method to deliver cancer-fighting drugs directly to milk ducts

One of every eight women in the United States will develop breast cancer. Though the incidence of breast cancer began decreasing in 2000, it is still the second-leading cause of cancer death in women.

25 Mar 2014

Researchers use retro approach to produce new drugs

This alternative approach to creating artificial organic molecules, called bioretrosynthesis, was first proposed four years ago by Brian Bachmann, associate professor of chemistry at Vanderbilt University. Now Bachmann and a team of collaborators report that they have succeeded in using the method to produce the HIV drug didanosine.

25 Mar 2014

IDRI awarded grant extension of $3.4M for identifying new leads and drug targets for tuberculosis

IDRI's drug discovery efforts continue to grow with a recently awarded grant extension of $3.4 million from the Bill & Melinda Gates Foundation. The additional funding was awarded to Tanya Parish, Ph.D., IDRI's Vice President of Drug Discovery, and supplements an earlier grant awarded in 2010, for a total of $7.8 million.

25 Mar 2014

Imaging cancer in children using MRI: an interview with Dr. Heike E. Daldrup-Link, Stanford University School of Medicine

There have been a number of scientific publications recently that suggest that the radiation exposure from imaging tests can induce secondary cancers later in life.

21 Mar 2014

ZL105 drug could potentially replace currently used anticancer drugs, study finds

A revolution in cancer treatment could soon be underway following a breakthrough that may lead to a dramatic improvement in cancer survival rates.

21 Mar 2014

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

The Global Health Innovative Technology Fund, a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced three grants worth a total of US$6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.

20 Mar 2014

Scientists step in with new way to determine drug safety without using animals

As some countries and companies roll out new rules to limit animal testing in pharmaceutical products designed for people, scientists are stepping in with a new way to test therapeutic drug candidates and determine drug safety and drug interactions — without using animals.

19 Mar 2014

GenSpera enrolls first patient in Phase II trial of compound G-202 in patients with glioblastoma multiforme

GenSpera, Inc. (OTCQB:GNSZ) announced that the first patient was enrolled in the Phase II clinical trial of its lead compound, G-202, in patients who have glioblastoma multiforme (GBM), the most prevalent type of primary brain cancer.

18 Mar 2014

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that dosing has begun in its Phase IIa clinical study of its investigational compound IW-3718 in patients suffering from gastroesophageal reflux disease (GERD) who have not responded adequately to treatment with a proton pump inhibitor (PPI). Data are expected in the first half of 2015.

18 Mar 2014

Body clock's could be utilized to improve current therapies to delay onset of chronic lung diseases

The body clock's natural rhythm could be utilized to improve current therapies to delay the onset of chronic lung diseases.

From The University of Manchester 18 Mar 2014

Findings support development of cysteine protease inhibitors as new drug target for AD

A team of scientists from the University of California, San Diego School of Medicine, the Medical University of South Carolina and San Diego-based American Life Science Pharmaceuticals, Inc., report that cathepsin B gene knockout or its reduction by an enzyme inhibitor blocks creation of key neurotoxic pGlu-Aβ peptides linked to Alzheimer's disease (AD). Moreover, the candidate inhibitor drug has been shown to be safe in humans.

18 Mar 2014

Compound from "third-hand smoke" damages DNA and potentially cause cancer

Leftover cigarette smoke that clings to walls and furniture is a smelly nuisance, but now research suggests that it could pose a far more serious threat, especially to young children who put toys and other smoke-affected items into their mouths.

18 Mar 2014

Bisphenol A may promote prostate tumourigenesis

Bisphenol A, an organic compound that is ubiquitous in plastic products, may have a direct tumourigenic effect in the prostate, US researchers have shown.

17 Mar 2014

Research on diverse health benefits of oats in protecting heart

Eleven top scientists from around the globe presented the latest findings on the powerful compounds found in oats in a scientific session titled, Physicochemical Properties and Biological Functionality of Oats, at the 247th Annual Conference of the American Chemical Society in Dallas, TX

17 Mar 2014

Sensient Technologies files definitive proxy materials with SEC, sends letter to shareholders

Sensient Technologies Corporation announced today that it filed definitive proxy materials with the Securities and Exchange Commission (the "SEC") in connection with its 2014 Annual Meeting of Shareholders, to be held on April 24, 2014.

17 Mar 2014

Scientists develop new water purifier that could work with sunlight

Sunlight plus a common titanium pigment might be the secret recipe for ridding pharmaceuticals, pesticides and other potentially harmful pollutants from drinking water.

17 Mar 2014

Researcher discover new chemical class that attacks two key cancer cell building block targets

Imagine cutting down the growth of cancer cells at their earliest stages to halt tumor growth. Research conducted by leading cancer metabolism researchers at Stony Brook University, Paul M. Bingham, PhD, and Zuzana Zachar, PhD, is showing promise in this approach with their clinical investigation of a new class of compounds that disrupt cancer cell mitochondrial metabolism.

14 Mar 2014

Study: Blocking body's immune response greatly reduces disability after stroke

A new study in animals shows that using a compound to block the body's immune response greatly reduces disability after a stroke.

14 Mar 2014

Compound News and Research

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

State highlights: Fla. employees' unequal premiums; abuse by Calif. doctor alleged

Scientists develop new method to deliver cancer-fighting drugs directly to milk ducts

Researchers use retro approach to produce new drugs

IDRI awarded grant extension of $3.4M for identifying new leads and drug targets for tuberculosis

Imaging cancer in children using MRI: an interview with Dr. Heike E. Daldrup-Link, Stanford University School of Medicine

ZL105 drug could potentially replace currently used anticancer drugs, study finds

GHIT Fund announces grants to speed up innovative drug development for neglected diseases

Scientists step in with new way to determine drug safety without using animals

GenSpera enrolls first patient in Phase II trial of compound G-202 in patients with glioblastoma multiforme

Ironwood Pharmaceuticals starts Phase IIa clinical study of IW-3718 for gastroesophageal reflux disease

Body clock's could be utilized to improve current therapies to delay onset of chronic lung diseases

Findings support development of cysteine protease inhibitors as new drug target for AD

Compound from "third-hand smoke" damages DNA and potentially cause cancer

Bisphenol A may promote prostate tumourigenesis

Research on diverse health benefits of oats in protecting heart

Sensient Technologies files definitive proxy materials with SEC, sends letter to shareholders

Scientists develop new water purifier that could work with sunlight

Researcher discover new chemical class that attacks two key cancer cell building block targets

Study: Blocking body's immune response greatly reduces disability after stroke

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News